Matt Phipps
Stock Analyst at William Blair
(0.13)
# 4,101
Out of 4,711 analysts
16
Total ratings
18.18%
Success rate
-43.63%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Matt Phipps
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KROS Keros Therapeutics | Downgrades: Market Perform | n/a | $17.03 | - | 1 | Dec 12, 2024 | |
| UPB Upstream Bio | Initiates: Outperform | n/a | $16.21 | - | 1 | Nov 5, 2024 | |
| TENX Tenax Therapeutics | Initiates: Outperform | n/a | $5.61 | - | 1 | Sep 30, 2024 | |
| CGEM Cullinan Therapeutics | Initiates: Outperform | n/a | $11.60 | - | 1 | Apr 15, 2024 | |
| BMY Bristol-Myers Squibb Company | Downgrades: Market Perform | n/a | $57.33 | - | 1 | Oct 27, 2023 | |
| KZR Kezar Life Sciences | Downgrades: Market Perform | n/a | $6.38 | - | 2 | Mar 16, 2023 | |
| JANX Janux Therapeutics | Initiates: Outperform | n/a | $56.83 | - | 1 | Nov 14, 2022 | |
| GMAB Genmab | Initiates: Market Perform | n/a | $20.31 | - | 1 | Nov 14, 2022 | |
| ALRN Aileron Therapeutics | Downgrades: Market Perform | n/a | $1.75 | - | 1 | Jun 29, 2022 | |
| INKT MiNK Therapeutics | Initiates: Outperform | n/a | $0.52 | - | 1 | Nov 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $0.71 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $21.57 | - | 1 | Oct 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $146.47 | - | 2 | Jun 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | n/a | $41.85 | - | 1 | Apr 8, 2021 |
Keros Therapeutics
Dec 12, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $17.03
Upside: -
Upstream Bio
Nov 5, 2024
Initiates: Outperform
Price Target: n/a
Current: $16.21
Upside: -
Tenax Therapeutics
Sep 30, 2024
Initiates: Outperform
Price Target: n/a
Current: $5.61
Upside: -
Cullinan Therapeutics
Apr 15, 2024
Initiates: Outperform
Price Target: n/a
Current: $11.60
Upside: -
Bristol-Myers Squibb Company
Oct 27, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $57.33
Upside: -
Kezar Life Sciences
Mar 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $6.38
Upside: -
Janux Therapeutics
Nov 14, 2022
Initiates: Outperform
Price Target: n/a
Current: $56.83
Upside: -
Genmab
Nov 14, 2022
Initiates: Market Perform
Price Target: n/a
Current: $20.31
Upside: -
Aileron Therapeutics
Jun 29, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $1.75
Upside: -
MiNK Therapeutics
Nov 9, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.52
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $0.71
Upside: -
Oct 21, 2021
Initiates: Outperform
Price Target: n/a
Current: $21.57
Upside: -
Jun 8, 2021
Upgrades: Outperform
Price Target: n/a
Current: $146.47
Upside: -
Apr 8, 2021
Initiates: Outperform
Price Target: n/a
Current: $41.85
Upside: -